Roche (OTCMKTS:RHHVF – Get Free Report) is expected to be announcing its resultson Thursday, July 23rd. Analysts expect Roche to announce earnings of $12.51 per share and revenue of $37.6482 billion for the quarter.
Roche Price Performance
Shares of RHHVF opened at $412.26 on Tuesday. The business’s 50 day moving average price is $408.59 and its 200-day moving average price is $420.88. Roche has a 52 week low of $300.15 and a 52 week high of $490.33.
About Roche
Roche Holding AG, traded on the OTCMKTS under the symbol RHHVF, is a leading global healthcare company with two core business divisions: Pharmaceuticals and Diagnostics. The company focuses on developing innovative medicines and diagnostic tests that address serious diseases, driving advances in personalized healthcare and precision medicine.
In its Pharmaceuticals division, Roche pioneers targeted therapies across oncology, immunology, ophthalmology and neuroscience. Flagship products include monoclonal antibodies and small-molecule treatments such as Herceptin, Avastin and Actemra, which have become standards of care for cancer and autoimmune conditions.
Further Reading
- Five stocks we like better than Roche
- The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence
- Is Domino’s Stock Serving Up a Buying Opportunity?
- A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free
- Why Gold Miners Could Be the Market’s Biggest Comeback Story
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.
